BiotechTube

DBV712 IHRP

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peanut Allergy

Conditions

Peanut Allergy

Trial Timeline

Nov 24, 2017 → Jun 29, 2018

NCT ID
NCT03352726

About DBV712 IHRP

DBV712 IHRP is a phase 1 stage product being developed by DBV Technologies for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT03352726. Target conditions include Peanut Allergy.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03352726Phase 1Completed

Competing Products

20 competing products in Peanut Allergy

See all competitors
ProductCompanyStageHype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo IntramuscularAstellas PharmaPhase 1
33
ASP0892 + PlaceboAstellas PharmaPhase 1
33
ligelizumab + PlaceboNovartisPhase 3
77
remibrutinib + placeboNovartisPhase 2
52
QGE031 + PlaceboNovartisPhase 2
52
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3
77
Dupilumab + Placebo matching dupilumab + AR101SanofiPhase 2
51
DupilumabSanofiPhase 2
51
Etokimab + PlaceboAnaptysBioPhase 2
47
Epicutaneous Immunotherapy + placebo of peanutDBV TechnologiesPhase 2
47
Viaskin Peanut 250 mcg + PlaceboDBV TechnologiesPhase 3
72
Viaskin PeanutDBV TechnologiesPre-clinical
18
Viaskin Peanut 50 mcg + Viaskin Peanut 100 mcg + Viaskin Peanut 250 mcg + Viaskin PlaceboDBV TechnologiesPhase 2
47
DBV712 250 mcgDBV TechnologiesPhase 3
72
Whole peanut extract + Placebo formulationDBV TechnologiesPhase 1
28
Viaskin Peanut 250 mcgDBV TechnologiesPhase 2
47
DBV712 + DBV712DBV TechnologiesPhase 3
72
Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo + Part B Viaskin Peanut 250 mcg + Part B PlaceboDBV TechnologiesPhase 3
72
Viaskin Peanut 250mcg + PlaceboDBV TechnologiesPhase 3
72
Viaskin Peanut 250µgDBV TechnologiesPhase 3
72

Other Products from DBV Technologies

Viaskin Peanut 250 mcg + PlaceboPhase 3
72
DBV712 250 mcgPhase 3
72
DBV712 + DBV712Phase 3
72
Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo + Part B Viaskin Peanut 250 mcg + Part B PlaceboPhase 3
72
Viaskin Peanut 250mcg + PlaceboPhase 3
72